Treatment for Hepatitis C Virus Infection in Adults: Comparative Effectiveness
Dual Therapy Containing Pegylated Interferon Alfa-2a Versus Dual Therapy Containing Pegylated Interferon Alfa-2b (1 of 2)
The likelihood of achieving an SVR was similar for dual therapy with ribavirin plus pegylated interferon alfa-2b and ribavirin plus pegylated interferon alfa-2a (although the likelihood appeared to be slightly lower for dual therapy with ribavirin + pegylated interferon alfa 2b). The strength of evidence for this finding was rated moderate. Seven trials conducted in patients with hepatitis C virus (HCV) genotype 1, 2, 3 or 4 infection found that dual therapy with standard doses of pegylated interferon alfa-2b plus ribavirin was associated with a lower likelihood of achieving a sustained virologic response (SVR) than pegylated interferon alfa-2a plus ribavirin (pooled relative risk, 0.87; 95-percent confidence interval [95% CI], 0.80 to 0.95), with an absolute difference in SVR rates of 8 percentage points (95% CI, 3 to 14). Absolute SVR rates were 38–62 percent for dual therapy with pegylated interferon alfa-2b versus 41–71 percent for dual therapy with pegylated interferon alfa-2a.
- Chou R, Hartung D, Rahman B, et al. Treatment for Hepatitis C Virus Infection in Adults: A Comparative Effectiveness Review. Evidence Report No. 76 (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-2007-10057-I). Rockville, MD: Agency for Healthcare Research and Quality; August 2012. AHRQ Publication No. 12-EHC113-EF. Available at www.effectivehealthcare.ahrq.gov/hepctreatment.cfm.
Your slide tray is being processed.